1800 244 735

Helpline (02) 9874 9777

Coming soon from the 2013 Huntington's Disease World Congress: Buzzilia!

Jeff Carroll and Ed Wild will be reporting on the hottest science news from the 2013 World Congress on Huntington’s Disease in Rio de Janeiro, from Sunday 15th to Wednesday 18th September, in a special feature we’re calling Buzzilia!

The World Congress on Huntington’s Disease

The World Congress on Huntington’s Disease is the biggest regular meeting of people affected by Huntington’s disease, family members, friends, carers, scientists and health professionals. This year, for the first time ever, it’s being held in Latin America – in Rio de Janeiro, Brazil.

South American families, especially those in Venezuela, were crucial to the discovery of the genetic cause of HD and the disease remains more common there than elsewhere. In recent years, great strides have been made in Latin America for HD-affected people – including the establishment of the South American HD Network, the Red Latino-Americana de Huntington (RLAH) and a big upsurge in research activity. So it’s great to see the World Congress head there for the first time.

The HD World Congress is a unique opportunity for the global Huntington’s disease community to come together and for people to learn from each other and share news, progress and excitement.

For family members, it’s a great opportunity to hear directly about the latest progress towards treatments for HD, to meet scientists who are working on HD, and to find out what’s working, what’s not and what might be around the corner. Chat to your favorite researcher and thank them – or tell them to hurry up!

For scientists and care professionals, it’s a valuable time to get to know HD family members and hear about their lives. It is incredibly motivating for scientists to meet the people their work is trying to help.

Announcing … Buzzilia!

We’re excited to announce that your HDBuzz editors-in-chief, Dr Jeff Carroll and Dr Ed Wild, will be presenting a nightly feature at the World Congress. In keeping with a now-established tradition of terrible puns – remember Oz Buzz and EuroBuzz? – we’re calling this year’s coverage Buzzilia!

Buzzilia will bring you all the hottest science news from the World Congress, with the HDBuzz ethos: the latest research news – brought to you by scientists – in plain language – for the global HD community.

We’ll be joined by special guests for interviews, news reports and some more light-hearted features that will inform and entertain.

Buzzilia is supported by the World Congress Organizing Committee and our funding partners.

Of course, not everyone can make it to Rio. So to emphasize the truly global nature of the HD Community, we’ll again be using internet and social media to connect with the hundreds of thousands of HD-affected people around the globe.

We’ll be posting news updates every day of the Congress at HDBuzz.net, and full video of our coverage online shortly afterwards. But if you don’t want to miss a thing, follow HDBuzzFeed on Twitter.

We look forward to seeing you in Rio, or having you join us online for a week of exciting news updates from the World Congress.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Published date: 15 July, 2020

Dopamine is an important chemical messenger in the brain that becomes imbalanced in Huntington’s disease. Researchers recently described a creative way to restore the balance and treat symptoms in HD mice, using an antihistamine drug that acts on hybrid dopamine receptors. It’s an innovative approach to HD therapeutics, but don’t start reaching for allergy meds ... Read more HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.